Corey Davis analyst

Currently out of the existing stock ratings of Corey Davis, 1 are a SELL (2.33%), 35 are a BUY (81.4%), 7 are a HOLD (16.28%).

Corey Davis

Work Performance Price Targets & Ratings Chart

Analyst Corey Davis, currently employed carries an average stock price target met ratio of 71.43% that have a potential upside of 57.54% achieved within 405 days. Previously, Corey Davis worked at LIFESCI.

Corey Davis’s has documented 68 price targets and ratings displayed on 7 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ZYNE, Zynerba Pharmaceuticals at 15-Aug-2023.

Wall Street Analyst Corey Davis

Analyst best performing recommendations are on CARA (CARA THERAPEUTIC).
The best stock recommendation documented was for CARA (CARA THERAPEUTIC) at 10/13/2016. The price target of $20 was fulfilled within 167 days with a profit of $11.91 (147.22%) receiving and performance score of 8.82.

Average potential price target upside

ENDP Endo International PLC TEVA Teva Pharma Industries Ltd ADR VNDA Vanda Pharmaceuticals PCRX Pacira Pharmaceuticals AERI Aerie Pharmaceuticals . ZYNE Zynerba Pharmaceuticals CARA Cara Therapeutic

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$1

$0.86 (614.29%)

$2

2 years 7 months 9 days ago
(09-May-2022)

4/5 (80%)

$-0.2 (-16.67%)

77

Hold

$2

$1.86 (1328.57%)

$4

2 years 7 months 9 days ago
(09-May-2022)

7/9 (77.78%)

$0.8 (66.67%)

151

Hold

$1

$0.86 (614.29%)

$3

2 years 7 months 12 days ago
(06-May-2022)

9/17 (52.94%)

$-0.42 (-29.58%)

77

Buy

$11

$10.86 (7757.14%)

$11

2 years 9 months 9 days ago
(09-Mar-2022)

3/6 (50%)

$8.53 (345.34%)

103

Hold

3 years 1 months 13 days ago
(05-Nov-2021)

1/3 (33.33%)

$10.51 (91.47%)

83

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Corey Davis?

On 2009

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?